Table 2. Aortic hemodynamics and pulse wave characteristics of women 3 years after cessation of placebo or postmenopausal hormone therapy
VariableOriginal treatment groupP‐value
PL (n = 26)oCEE (n = 18)tE2 (n = 23)
Aortic SBP, mm Hg 115 (104, 126)114 (104, 121)116 (111, 122)0.756
Aortic DBP, mm Hg76 (69, 84)75 (70, 78)77 (70, 80)0.927
Pulse pressure amplification, %119 (113, 128)119 (114, 124)118 (113, 122)0.593
Augmented pressure, mm Hg13 (9, 16)14 (11, 17)13 (11, 17)0.851
AIx, %34 (29, 40)33 (28, 39)33 (30, 39)0.983
AIx at 75 bpm, %30 (23, 33)28 (25, 33)27 (23, 31)0.895
Ew, dyne•cm2•s2706 (1896, 3432)2835 (2263, 3749)3083 (2217, 4118)0.802
Δtr, msec141 (135, 147)139 (132, 143)142 (130, 153)0.514
  • Data are presented as median (25th, 75th percentile). AIx, augmentation index; AIx at 75 bpm, augmentation index adjusted for a heart rate of 75 beats per minute; DBP, diastolic blood pressure; mm Hg, millimeters of mercury; Ew, wasted left ventricular pressure energy; oCEE, oral conjugated equine estrogen; SBP, systolic blood pressure; tE2, transdermal 17β‐estradiol; Δtr, systolic duration of the reflected wave.